Nanobiotix, an emerging nanomedicine company focused on cancer therapy, announced today that the European Patent Office (EPO) has issued Patent No. 1744789 to the Company, related to its "novel activable particles that can be used in the health sector."
More specifically, the patent protects "composite particles that can
generate free radicals or heat when excited by X-rays, and to the uses thereof
in health, particularly human. The inventive particles comprise an inorganic-based,
and optionally organic-based, nucleus and can be activated in vivo, in order
to label or alter cells, tissues or organs. (The patent protection) also relates
to methods for the production of said particles, and to pharmaceutical or diagnostic
compositions containing same."
“We are extremely pleased that our platform technology, nanoXray, is
now patent-protected throughout the European Union. We are hopeful that we will
soon receive similar patent protection in the United States as well,”
said Laurent Lévy, Ph.D., President and CEO of Nanobiotix and Co-President
of the French Technology Platform on Nanomedicine (FTPN). “NanoXray is
designed to allow the precise destruction of cancer cells via the controlled
application of an outside-the-body energy source—a standard X-ray. Of
course, protecting this intellectual property is key to long-term commercial
“The nanoXray platform allows for the controlled generation of physical
reactions in targeted cells when triggered by the application of an external
energy source — a standard X-ray. This may have significant ramifications
for cancer therapy in the not-too-distant future,” added Paras N. Prasad,
Ph.D., one of the world’s leading authorities on nanotechnology, who is
a co-founder of Nanobiotix and Executive Director of the Institute for Lasers,
Photonics and Biophotonics at SUNY (Buffalo).